Scientists are designing "tripless" drugs that mimic psychedelics like LSD and ketamine to treat mood disorders, depression, and addiction. The implications could be significant.
Principal Investigators in Full time, Principal Investigator, Biomedicine with Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. Apply Today.
A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.
Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.